Home / Reports / EMA report shows generics applications down but biosimilars up

EMA report shows generics applications down but biosimilars up Posted 19/10/2012

EMA’s mid-year report for 2012 has shown that the number of generics applications is much lower than the agency has predicted, while for biosimilars it is the opposite.

The report, which covers the period of January to June 2012, shows a significant decrease in the number of generics applications compared to the second quarter of 2011. In fact, during 2012 there have been so far only 11 generics applications compared to 21 during the same period in 2011.

In the same period of January to June 2012, the agency reports an increase in applications for biosimilars, see Table 1. In the first six months of 2012, EMA has already received six applications for ‘similar biological products’ or biosimilars compared to 0, 0 and 1 application during the same period in 2011, 2010 and 2009, respectively.

While the agency expects the number of generics applications to remain low, it does expect there will be an increase later in the year. EMA has, however, still revised its forecast down from a prediction of 32 generics applications to only 18 applications expected during 2012, see Table 1. Biosimilars on the other hand have already exceeded their forecast of five applications for the whole of 2012 in just the first six months. EMA has therefore revised its forecast for biosimilars to eight applications during 2012.

Table 1: Applications submitted to EMA

Procedure

2012
(Q1-Q2)
(actual)

2012
(forecast)

2012
revised forecast

2011
(Q1-Q2)

2010
(Q1-Q2)

2009
(Q1-Q2)

New non-orphan medicinal products

25

52

50

15

18

14

New orphan medicinal products

8

13

17

8

6

4

Biosimilars

6

5

8

0

0

1

Generics

11

32

18

21

8

31

Hybrid and abridged applications

2

7

5

4

2

1

Scientific opinions for non-EU markets

0

1

1

0

1

0

Paediatric-use marketing authorisations

0

0

0

1

0

0

Advanced therapy re-registration

1

2

2

0

0

N/A

N/A = not applicable

It appears that the patent cliff and generics competition is not affecting the number of new drug applications. EMA has already received 25 applications for non-orphan drugs in the first six months of 2012 compared to only 15 during the same period in 2011.

Related articles

EMA publishes revised biosimilar Q&A document for patients

EMA to accept biosimilar reference medicines from outside EEA

EMA receives second application for biosimilar infliximab

Biosimilars approved in Europe

Permission granted to reproduce for personal and educational use only. All other reproduction, copy, retransmission or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: EMA

Comments (0)